Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from DRI Healthcare ( ($TSE:DHT.UN) ).
DRI Healthcare Trust announced that KalVista Pharmaceuticals received a notice from the FDA indicating a delay in the PDUFA goal date for sebetralstat due to resourcing constraints. The FDA has not requested additional data and expects to make a decision within four weeks, which may impact KalVista’s market positioning and stakeholder expectations.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Hold with a C$15.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
Spark’s Take on TSE:DHT.UN Stock
According to Spark, TipRanks’ AI Analyst, TSE:DHT.UN is a Neutral.
DRI Healthcare Trust’s strong balance sheet and effective cash flow management are overshadowed by profitability challenges due to revenue decline and net losses. Technical analysis shows a bearish trend, and valuation concerns arise from negative earnings. However, recent corporate events indicate a positive outlook with improved financial results and strategic management, providing a moderate boost to the overall score.
To see Spark’s full report on TSE:DHT.UN stock, click here.
More about DRI Healthcare
DRI Healthcare Trust, managed by DRI Capital Inc., is a leader in global pharmaceutical royalty monetization. Since its IPO in 2021, the Trust has invested over $1.0 billion in acquiring royalties on more than 25 drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula, and Zytiga. The Trust’s units are traded on the Toronto Stock Exchange under the symbols ‘DHT.UN’ and ‘DHT.U’.
Average Trading Volume: 42,448
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$733.2M
For a thorough assessment of DHT.UN stock, go to TipRanks’ Stock Analysis page.